Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Follow our page for more such updates: News Source: #CagriSema #NovoNordisk #Obesity #ObesityTreatment #WeightLoss #GLP1 #Incretins #MetabolicHealth #Cardiometabolic #Phase3 #ClinicalTrials #REDEFINE4 #DrugDevelopment #PharmaInnovation To view or add a comment, sign in Novo Nordisk's CagriSema Delivers 23% Weight Loss but Misses Non-Inferiority vs Tirzepatide in REDEFINE-4 Novo Nordisk reported topline results from the Phase 3 REDEFINE-4 trial evaluating CagriSema (cagrilintide + semaglutide) in obesity
doi: 10.3181/00379727-149-38889 51 QiG.MiY.ShiX.GuH.BrintonR
For the UK, UKCA marking is essential
The content on the SheMed blog is provided for general informational and educational purposes only
